Diagnosis of bladder cancer using 18F-labeled α-methyl-phenylalanine tracers in a mouse model
- 6 March 2020
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 34 (5) , 329-336
Abstract
Objective Although 2-18F-fluoro-2-deoxy-glucose (18F-FDG) has established roles in the diagnosis of a variety of cancers, it has limited value in the detection of primary/recurrent lesions in the bladder, mainly because of interference by the pooled radioactivity in the urine. Our previous study revealed promising properties of l- and d-2-18F-α-methyl-phenylalanine (2-18F-FAMP) as radiotracers; i.e., their rapid blood clearance and low renal accumulation. In the present study we evaluated the utility of l- and d-2-18F-FAMP for imaging bladder cancer in a mouse model. Methods We used the human bladder cancer cell line HT1376 to prepare a bladder cancer xenograft model in mice bearing both orthotopic and subcutaneous tumors. Biodistribution and PET imaging studies were performed at 1 and 3 h after injection of l-2-18F-FAMP or d-2-18F-FAMP. 18F-FDG was used as a control. Results At 1 h after injection, greater accumulations of both l-2-18F-FAMP and d-2-18F-FAMP were observed in the orthotopic tumors compared to 18F-FDG. The orthotopic tumor-to-muscle ratio of d-2-18F-FAMP was significantly higher than that of 18F-FDG (p < 0.01), because of the rapid blood clearance of d-2-18F-FAMP. l-2-18F-FAMP showed the highest subcutaneous tumor-to-muscle ratio (p < 0.01) due to its high subcutaneous tumor uptake. Compared to l-2-18F-FAMP, d-2-18F-FAMP exhibited faster clearance and lower kidney accumulation. In the PET imaging studies, l- and d-2-18F-FAMP both clearly visualized the orthotopic bladder tumors at 1 h after injection. Conclusion Our study showed that l-2-18F-FAMP and d-2-18F-FAMP have the potential to detect bladder cancer.Keywords
This publication has 18 references indexed in Scilit:
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerEuropean Urology, 2017
- Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumorsOncotarget, 2015
- Development of a Widely Usable Amino Acid Tracer: 76Br-α-Methyl-Phenylalanine for Tumor PET ImagingJournal of Nuclear Medicine, 2015
- Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision ApproachPLOS ONE, 2013
- Biological evaluation of 3-[18F]fluoro-α-methyl-d-tyrosine (d-[18F]FAMT) as a novel amino acid tracer for positron emission tomographyAnnals of Nuclear Medicine, 2013
- Intravesical drug delivery: Challenges, current status, opportunities and novel strategiesJournal of Controlled Release, 2010
- Imaging in Bladder Cancer: Present Role and Future PerspectivesUrologia Internationalis, 2010
- The effect of furosemide dose timing on bladder activity in oncology imaging with 18F-fluorodeoxyglucose PET/CTNuclear Medicine Communications, 2010
- 18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder CancerJournal of Nuclear Medicine, 2007
- Positron emission tomography for prostate, bladder, and renal cancerSeminars in Nuclear Medicine, 2004